

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM748627

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
MIDCAP FINANCIAL TRUST		08/15/2022	Statutory Trust: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	RADIUS HEALTH, INC.
<b>Street Address:</b>	22 Boston Wharf Road, 7th Floor
<b>City:</b>	Boston
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02210
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Name:</b>	RADIUS PHARMACEUTICALS, INC.
<b>Street Address:</b>	22 Boston Wharf Road, 7th Floor
<b>City:</b>	Boston
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02210
<b>Entity Type:</b>	Corporation: DELAWARE

## PROPERTY NUMBERS Total: 9

Property Type	Number	Word Mark
<b>Registration Number:</b>	3687535	RADIUS
<b>Registration Number:</b>	5433991	TYMLOS
<b>Serial Number:</b>	88760408	SYNCAN
<b>Serial Number:</b>	87796289	RADIUS
<b>Serial Number:</b>	87698393	TIMLOZE
<b>Serial Number:</b>	88640220	TYMLOS
<b>Serial Number:</b>	88684064	VENSITY
<b>Serial Number:</b>	86953474	VENSITY
<b>Serial Number:</b>	88151501	ELADYNOS

## CORRESPONDENCE DATA

Fax Number:

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

TRADEMARK

**Email:** akwon@cov.com  
**Correspondent Name:** COVINGTON & BURLING LLP  
**Address Line 1:** ONE CITY CENTER, 850 TENTH ST NW  
**Address Line 2:** ATTN: PATENT DOCKET  
**Address Line 4:** WASHINGTON, D.C. 20001

<b>ATTORNEY DOCKET NUMBER:</b>	34550.00094
<b>NAME OF SUBMITTER:</b>	Ashley M. Kwon
<b>SIGNATURE:</b>	/Ashley M. Kwon/
<b>DATE SIGNED:</b>	08/15/2022

**Total Attachments: 7**

source=MidCap Financial Trust- IP Termination#page1.tif  
source=MidCap Financial Trust- IP Termination#page2.tif  
source=MidCap Financial Trust- IP Termination#page3.tif  
source=MidCap Financial Trust- IP Termination#page4.tif  
source=MidCap Financial Trust- IP Termination#page5.tif  
source=MidCap Financial Trust- IP Termination#page6.tif  
source=MidCap Financial Trust- IP Termination#page7.tif

**RELEASE OF SECURITY INTEREST  
IN INTELLECTUAL PROPERTY**

This Release of Security Interest in Intellectual Property, dated as of August 15, 2022 (the “**Release**”), is made by **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust, (“**Agent**”), in favor **RADIUS HEALTH, INC.**, a Delaware corporation, and **RADIUS PHARMACEUTICALS, INC.**, a Delaware corporation (each, a “**Grantor**” and collectively, the “**Grantors**”):

WHEREAS, pursuant to that certain Intellectual Property Security Agreement, dated as of January 10, 2020, as amended by that certain Omnibus Reaffirmation Agreement and Joinder and Amendment to Pledge Agreement and Intellectual Property Security Agreement, dated as of March 3, 2021 (as may have been further amended, modified, restated, replaced or supplemented from time to time, the “**IP Security Agreement**”; capitalized terms used herein have the definition provided for in the IP Security Agreement), recorded with the United States Patent and Trademark Office (the “**USPTO**”) on January 15, 2020 at Reel/Frame No. 51618/200 (Patents) (as supplemented by (i) that recording on July 6, 2020 at Reel/Frame No. 53131/465 (Patents), (ii) that recording on March 17, 2021 at Reel/Frame No. 55632/653 (Patents) and (iii) that recording on March 17, 2021 at Reel/Frame No. 055632/17 (Patents)) and on January 15, 2020 at Reel/Frame No. 6838/823 (Trademarks) (as supplemented by (i) that recording on July 6, 2020 at Reel/Frame No. 6991/87 (Trademarks), (ii) that recording on March 17, 2021 at Reel/Frame No. 7223/194 (Trademarks) and (iii) that recording on March 17, 2021 at Reel/Frame No. 7223/237 (Trademarks)), the Grantors granted Agent, on behalf of the Lenders, a security interest in and to all of its right, title and interest in all of the Grantors’ intellectual property, including those listed on Schedules A and B thereto;

WHEREAS, the Grantors have requested that Agent release its security interest in and to the patent assets as more particularly described on Schedule A attached hereto (the “**Released Patents**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to the Trademarks as more particularly described on Schedule B attached hereto (the “**Released Trademarks**”, and together with the Released Patents, the “**Released IP Collateral**”).

NOW, THEREFORE, Agent, without recourse, representation or warranty and at the Grantors’ sole cost and expense, hereby releases all of its right, title and interest in and to the Released IP Collateral.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Agent has caused this Release of Security Interest in Intellectual Property to be duly executed and delivered by its duly authorized officer as of the date first written above.


**AGENT:**

**MIDCAP FINANCIAL TRUST**

as Agent

By: Apollo Capital Management, L.P.,  
its investment manager

By: Apollo Capital Management GP, LLC,  
its general partner

By:   
\_\_\_\_\_  
Name: Maurice Amsellem  
Title: Authorized Signatory

Schedule A

Patents

**Registered Patents:**

<b>Owner</b>	<b>Patent</b>	<b>Registration No.</b>	<b>Registration Date</b>
Radius Pharmaceuticals, Inc.	Selective Androgen Receptor Modulators	9,133,182	15-Sep-15
Radius Pharmaceuticals, Inc.	Selective Androgen Receptor Modulators	9,920,044	20-Mar-18
EISAI R&D MANAGEMENT CO., LTD.	Selective Estrogen Receptor Modulator	7,612,114	3-Nov-09
Radius Pharmaceuticals, Inc.	Selective Estrogen Receptor Modulator	7,960,412	14-Jun-11
Radius Pharmaceuticals, Inc.	Selective Estrogen Receptor Modulator	8,399,520	19-Mar-13
Duke University	Methods of Treating Cancer Using Selective Estrogen Receptor Modulators for RAD1901	9,421,264	23-Aug-16
Duke University	Methods of Treating Cancer Using Selective Estrogen Receptor Modulators for RAD1901	10,071,066	11-Sep-18
Duke University	Methods of Treating Cancer Using Selective Estrogen Receptor Modulators for RAD1901	10,420,734	24-Sep-19
Radius Pharmaceuticals, Inc.	Treatment of vasomotor symptoms with Selective estrogen receptor modulators	8,933,130	13-Jan-15
Radius Pharmaceuticals, Inc.	Polymorphic Forms of RAD1901-2HCL	10,385,008	20-Aug-19
Radius Pharmaceuticals, Inc.	Polymorphic Forms of RAD1901-2HCL	10,745,343	18-Aug-20
Radius Pharmaceuticals, Inc.	Therapeutic Regimens	9,555,014	31-Jan-17
Radius Health, Inc.	Method of Treating Osteoporosis Comprising Administration of PTHrP Analog	7,803,770	28-Sep-10
Radius Health, Inc.	Stable Composition Comprising a PTHrP Analogue	8,148,333	03-Apr-12

Owner	Patent	Registration No.	Registration Date
Radius Health, Inc.	Method of Drug Delivery for Bone Anabolic Protein	8,748,382	10-Jun-14
Radius Health, Inc.	Formulations of Abaloparatide, Transdermal Patches Thereof, and Uses Thereof	10,568,937	25-Feb-20
Radius Pharmaceuticals, Inc.	Polymorphic Forms of RAD1901-2HCl	11,148,996	21-Oct-19

**Patent Applications:**

Applicant	Patent	Application No.	Application Date
Duke University	Methods of Treating Cancer Using Selective Estrogen Receptor Modulators for RAD1901	16/041,416	20-Jul-18
Duke University	Methods of Treating Cancer Using Selective Estrogen Receptor Modulators for RAD1901	16/549,828	23-Aug-19
Radius Pharmaceuticals, Inc.	Methods of Treating Cancer	15/794,774	26-Oct-17
Radius Pharmaceuticals, Inc.	Combination Therapy	16/580,914	24-Sep-19
Radius Pharmaceuticals, Inc.	Combination Therapy	15/794,861	26-Oct-17
Radius Pharmaceuticals, Inc.	Methods For Treating Cancer	16/545,859	20-Aug-19
Radius Pharmaceuticals, Inc.	Methods for Treating Ovarian Cancer	16/336,358	25-Mar-19
Radius Pharmaceuticals, Inc.	Elacestrant In Combination With Abemaciclib In Women With Breast Cancer	PCT/US2019/063239	26-Nov-19
Radius Pharmaceuticals, Inc.	Anti-Tumor Activity of Elacestrant in Models Harboring ESR1 Mutations Resistant to Standard of Care Therapies	PCT/US2019/064980	6-Dec-19
Radius Pharmaceuticals, Inc.	Processes and Compounds	PCT/US2020/017777	11-Feb-20
Radius Pharmaceuticals, Inc.	Estrogen Receptor-Modulating Compounds	PCT/US2020/042903	21-Jul-20

Applicant	Patent	Application No.	Application Date
Radius Pharmaceuticals, Inc.	Polymorphic Forms of RAD1901-2HCl	16/921,684	06-Jul-20
Radius Pharmaceuticals, Inc.	Estrogen Receptor-Modulating Compounds	16/963,794	22-Jan-19
Radius Pharmaceuticals, Inc.	Methods for Treating Cancer	16/985,021	04-Aug-20
Duke University	Method of Treating Cancer Using Selective Estrogen Receptor Modulators	16/986,492	06-Aug-20
Radius Pharmaceuticals, Inc.	Polymorphic Forms of RAD1901-2HCl	17/257,372	31-Dec-20
Radius Health, Inc.	Formulations of PTHrP Analogues, Transdermal Patches Thereof, and Uses Thereof	15/948,953	09-Apr-18
Radius Health, Inc.	Abaloparatide Formulations and Methods of Testing, Storing, Modifying, and Using Same	16/553,889	28-Aug-19
Radius Health, Inc.	Methods for Detecting Neutralizing Antibodies to Parathyroid Hormone (PTH) and Parathyroid Hormone-Related Peptide (PTHrP) Analog	PCT/IB2020/050200	10-Jan-20
Radius Health, Inc.	Methods of Improving Spinal Fusion With Abaloparatide	62/899,633	12-Sept-19
Radius Health, Inc.	Treatment of Long Bone Fractures With Abaloparatide	63/134,027	05-Jan-21
Radius Health, Inc.	Method of Treating Osteoporosis Comprising Administration of PTHrP Analog	17/133,968	24-Dec-20
Radius Health, Inc.	Method of Drug Delivery for PTH, PTHrP and Related Peptides	17/008,603	31-Aug-20
Radius Health, Inc.	Formulations of Abaloparatide, Transdermal Patches Thereof, and Uses Thereof	16/733,779	03-Jan-20
Radius Health, Inc.	Uses of PTHrP Analogue in Reducing Fracture Risk	16/903,256	16-Jun-20
Radius Pharmaceuticals, Inc.	Stable Cannabinoid Formulations	14/724,351	28-May-15
Radius Pharmaceuticals, Inc.	Stable Cannabinoid Formulations	14/815,936	31-Jul-15

Applicant	Patent	Application No.	Application Date
Radius Pharmaceuticals, Inc.	Stable Cannabinoid Formulations	15/166,476	27-May-16
Radius Pharmaceuticals, Inc.	Stable Cannabinoid Formulations	15/253,010	31-Aug-16
Radius Pharmaceuticals, Inc.	Stable Cannabinoid Formulations	15/499,178	27-Apr-17
Radius Pharmaceuticals, Inc.	Stable Cannabinoid Formulations	15/712,515	22-Sept-17

**Patent Licenses:**

Title	Jurisdiction	Application Serial No.	Filing Date
Methods of Manufacturing Cannabidiol and Intermediates of Manufacturing Cannabidiol	US	62/846,279	10-May-19
Methods of Manufacturing Cannabidiol or Cannabidiol and Intermediates of Manufacturing Cannabidiol or Cannabidiol	US	16/870,637	08-May-20
Methods of Manufacturing Cannabidiol or Cannabidiol and Intermediates of Manufacturing Cannabidiol or Cannabidiol	PCT	PCT/IB2020/000365	08-May-20
Cannabidiol Nanocrystal Compositions	US	62/856,526	03-Jun-19
Cannabidiol Nanocrystal Compositions	US	16/874,300	14-May-20
Cannabidiol Nanocrystal Compositions	PCT	PCT/IB2020/000474	14-May-20
Self-Emulsifying Cannabidiol Formulations	US	62/847,991	15-May-19
Self-Emulsifying Cannabidiol Formulations	US	16/874,225	15-May-20
Self-Emulsifying Cannabidiol Formulations	PCT	PCT/IB2020/000610	14-May-20



Schedule B

Trademarks

**Registered Trademarks:**

Owner	Mark	Registration No.	Registration Date
Radius Health, Inc.	RADIUS	3687535	22-Sep-09
Radius Health, Inc.	TYMLOS	5433991	27-March-18

**Trademark Applications:**

Applicant	Mark	Application No.	Application Date
Radius Pharmaceuticals, Inc.	SYNCAN	88-760-408	15-Jan-20
Radius Health, Inc.	RADIUS	87-796,289	13-Feb-18
Radius Health, Inc.	TIMLOZE	87-698,393	27-Nov-17
Radius Health, Inc.	TYMLOS	88-640,220	03-Oct-19
Radius Health, Inc.	VENSITY	88-684,064	07-Nov-19
Radius Health, Inc.	VENSITY	86-953,474	25-Mar-16
Radius Health, Inc.	ELADYNOS	88-151,501	11-Oct-18